222 related articles for article (PubMed ID: 23591788)
1. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.
Rowe JM; Löwenberg B
Blood; 2013 Jun; 121(24):4838-41. PubMed ID: 23591788
[TBL] [Abstract][Full Text] [Related]
2. Why is it so difficult to use gemtuzumab ozogamicin?
Sylvie Castaigne
Blood; 2013 Jun; 121(24):4813-4. PubMed ID: 23766456
[TBL] [Abstract][Full Text] [Related]
3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
4. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
Goldenson BH; Goodman AM; Ball ED
Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J; Wang ES
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
[TBL] [Abstract][Full Text] [Related]
7. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
O'Hear C; Rubnitz JE
Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
[TBL] [Abstract][Full Text] [Related]
8. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
11. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
12. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
13. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
[TBL] [Abstract][Full Text] [Related]
14. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
15. Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).
Middeldorf I; Galm O; Osieka R; Jost E; Herman JG; Wilop S
Am J Hematol; 2010 Jul; 85(7):477-81. PubMed ID: 20575043
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
17. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
19. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
Kell J
Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]